Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service tumor & fibroid embolization cases in Michigan: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 11% on average (118 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 7 | 322 | 45% |
| 2020 | 3 | 317 | 51% |
| 2021 | 5 | 315 | 55% |
| 2022 | 6 | 330 | 59% |
| 2023 | 3 | 304 | 63% |
| 2024 | 7 | 565 | 66% |
| 2025 from claims | – | 895 724–1,051 | 67% |
| 2026 forecast | – | 973 762–1,222 | 67% |
| 2027 forecast | – | 1,047 776–1,384 | 68% |
| 2028 forecast | – | 1,126 797–1,554 | 69% |
| 2029 forecast | – | 1,209 822–1,734 | 70% |
| 2030 forecast | – | 1,298 851–1,927 | 70% |
Chemo- and radioembolization of liver tumors, uterine fibroid and other organ embolization (one code covers all). Professional codes (what the surgeon bills): CPT 37243.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Michigan; 3 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 22% hospital outpatient, 78% office. The share outside the hospital has moved +78 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Hospital outpatient | Office |
|---|---|---|
| 2026 · ~970 | ~150 | ~820 |
| 2027 · ~1,000 | ~130 | ~920 |
| 2028 · ~1,100 | ~120 | ~1,000 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: hospital outpatient about 11% (22% in 2025), office about 89% (78% in 2025).
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Illinois | 14 | 674+3.6%/yr | +3.6%/yr | 0.5 | 49% | 1,750 in 2030+17%/yr |
| Missouri | 6 | 541+7.4%/yr | +7.4%/yr | 0.9 | 56% | 860 in 2030+8.1%/yr |
| Ohio | 7 | 370+1.9%/yr | +1.9%/yr | 0.3 | 67% | 1,280 in 2030+23%/yr |
| Wisconsin | 4 | 296+1.8%/yr | +1.8%/yr | 0.5 | 0% | 330 in 2030+1.9%/yr |
| Indiana | 5 | 282+1.3%/yr | +1.3%/yr | 0.4 | 61% | 580 in 2030+13%/yr |
| Minnesota | 4 | 239+0.6%/yr | +0.6%/yr | 0.5 | 45% | 380 in 2030+7.9%/yr |
| Iowa | 3 | 178+14%/yr | +14%/yr | 0.4 | 0% | 260 in 2030+6.8%/yr |
| Kansas | 3 | 164+3.8%/yr | +3.8%/yr | 0.4 | 65% | 580 in 2030+24%/yr |
| Nebraska | 2 | 116+16%/yr | +16%/yr | 0.4 | 23% | 210 in 2030+10%/yr |
| South Dakota | 2 | 101+20%/yr | +20%/yr | 0.8 | 42% | 180 in 2030+9.6%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Breast biopsy & localization | 102 | 5,736−6.4%/yr | −6.4%/yr | 7.31.0× | 5% | 5,320 in 2030−1.2%/yr |
| Tumor ablation | 0 | 228−3.3%/yr | −3.3%/yr | 0.30.8× | 0% | 370 in 2030+8.4%/yr |
Tumor & fibroid embolization in every state, and its device makers · Every procedure market in Michigan · Every state · Compare with Illinois
Exact Sciences leads with 48% of company spending on these surgeons in 2025, +8 pts on 2024.
In 2025, 19 companies reported engagement with Michigan’s surgeons worth $273K in consulting, speaking, meals and travel tied to these products, about $39K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 16 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.